相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors
Jiawan Wang et al.
CANCER RESEARCH (2021)
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial
Michael J. Fisher et al.
NATURE MEDICINE (2021)
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience
Vera Espirito Santo et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
An Update on Neurofibromatosis Type 1-Associated Gliomas
Mina Lobbous et al.
CANCERS (2020)
Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
Geraldine Helen O'Sullivan Coyne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities
Laura J. Klesse et al.
ONCOLOGIST (2020)
Current status of MEK inhibitors in the treatment of plexiform neurofibromas
Andrea M. Gross et al.
CHILDS NERVOUS SYSTEM (2020)
Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors
Jiawan Wang et al.
CANCER RESEARCH (2020)
Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas
Lauren H. Boal et al.
CLINICAL CANCER RESEARCH (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
Sabine Mueller et al.
NEURO-ONCOLOGY (2020)
Trametinib Induces Neurofibroma Shrinkage and Enables Surgery
Pia Vaassen et al.
NEUROPEDIATRICS (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
Sebastien Perreault et al.
BMC CANCER (2019)
Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a Trial
Ouidad Zehou et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity
Kavitha Nutakki et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study.
Geoffrey Brian McCowage et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher et al.
CURRENT ONCOLOGY REPORTS (2017)
Neurofibromatosis type 1
David H. Gutmann et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2017)
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M. Schlumberger et al.
ANNALS OF ONCOLOGY (2017)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study
Brian Weiss et al.
NEURO-ONCOLOGY (2015)
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Nancy Ratner et al.
NATURE REVIEWS CANCER (2015)
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Brigitte C. Widemann et al.
NEURO-ONCOLOGY (2014)
Sirolimus for Non-Progressive NF1-Associated Plexiform Neurofibromas: An NF Clinical Trials Consortium Phase II Study
Brian Weiss et al.
PEDIATRIC BLOOD & CANCER (2014)
Phase II Trial of Pirfenidone in Children and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Brigitte C. Widemann et al.
PEDIATRIC BLOOD & CANCER (2014)
Optimizing biologically targeted clinical trials for neurofibromatosis
David H. Gutmann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
Kent A. Robertson et al.
LANCET ONCOLOGY (2012)
Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis
Scott R. Plotkin et al.
PLOS ONE (2012)
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service
D. G. Evans et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
NF1 plexiform neurofibroma growth rate by volumetric MRI - Relationship to age and body weight
E. Dombi et al.
NEUROLOGY (2007)
Use of the National Institutes of Health Criteria for diagnosis of neurofibromatosis 1 in children
K DeBella et al.
PEDIATRICS (2000)
分享论文
